Medicine for treating rheumatic heart disease

Abstract

The invention relates to a medicine for treating rheumatic heart disease. The medicine is prepared from the following medicinal raw materials in parts by weight: 22 parts of caudate sweetleaf roots, 12 parts of radix euphorbiae, 9 parts of cortex erythrinae, 7 parts of radix asteris, 12 parts of macrosolen bibracteolatus, 10 parts of scutellaria orthocalyx and 12 parts of herba artemisiae annuae. According to the medicine, caudate sweetleaf roots have the effects of clearing heat, inducing diuresis, cooling blood, stopping bleeding, expelling wind and relieving pain; radix euphorbiae has the effects of stopping bleeding by astringency, relieving dysentery and killing parasites; cortex erythrinae has the effects of dispelling wind, drying dampness, relaxing muscles and tendons, removing obstructionfrom meridians, killing parasites and relieving itching; radix asteris has the effects of moistening lung, descending qi, eliminating phlegm and relieving cough; macrosolen bibracteolatus has the effect of removing wind-dampness; scutellaria orthocalyx has the effects of purging internal fire, relieving asthma, removing toxicity and diminishing swelling; herba artemisiae annuae has the effects of clearing heat, inducing diuresis and removing jaundice. The medicinal materials are combined to achieve the effects of promoting blood circulation to remove blood stasis, calming heart, tonifying lung, warming yang, inducing diuresis, tonifying qi and consolidating depletion. The medicine can be used for safely and effectively treating rheumatic heart disease.

Description

technical field [0001] The invention relates to a traditional Chinese medicine, in particular to a medicine for treating rheumatic heart disease. Background technique [0002] Rheumatic heart disease, referred to as rheumatic heart disease for short, is a common connective tissue disease, which refers to the heart valve disease caused by the activity of rheumatic fever and involving the heart valve. Manifested as mitral valve, tricuspid valve, aortic valve in one or more valve stenosis and (or) insufficiency. Clinically, stenosis or regurgitation often exist at the same time, but one kind is often the main one. In the early stage of the disease, there are often no obvious symptoms, but in the later stage, symptoms of cardiac decompensation such as palpitation, shortness of breath, fatigue, cough, lower extremity edema, and pink frothy sputum are manifested. For the pathogenesis of rheumatic fever, modern medicine once had streptococcal toxin theory, allergy theory, virus i...

AI Technical Summary

Problems solved by technology

[0008] ① Mitral regurgitation

Patients with atrial fibrillation, pulmonary hypertension, systemic embolism and functional tricuspid regurgitation should also undergo surgery, but the risk of surgery increases

Images